HER2+ Breast Cancer – Global Drug Forecast and Market Analysis to 2030
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData valued the 8MM HER-2 + breast cancer market at $10.4 billion in 2020 and expects the market to increase at a low compound annual growth rate (CAGR) of more than 1%. This growth will be driven by the anticipated launches of five pipeline agents, the expansion of several currently approved agents into earlier lines of therapy, and a collective increase in the diagnosed incident population across the 8MM. Growth will be substantially inhibited by generic and biosimilar erosion following the expiry of multiple patents of market-leading brands. These include Roche/Genentech’s Perjeta (pertuzumab), Herceptin (trastuzumab), and Kadcyla (T-DM1), which constitute the majority of sales across the 8MM in 2020. Furthermore, expected patent expiries of Puma Biotechnology’s Nerlynx (neratinib) and Seagen’s Tukysa (tucatinib) will further suppress market growth.
The US is the largest market, accounting for more than 50% of total HER2+ breast cancer sales in 2020. GlobalData expects the US market share to remain stable over the forecast period, as the 5EU markets will see their market share decline, while China will see its market share increase.
Overview of HER2+ breast cancer global drug market
For more insights on this report, download a free report sample
What are the market dynamics in the HER2+ breast cancer market?
Breast cancer is not a single disease, but rather a group of several different tumor subtypes. Although many subtypes exist, they are generally categorized by the presence or absence of hormonal receptors (HRs), including estrogen receptor (ER) and the progesterone receptor (PR), in addition to human epidermal growth factor receptor 2 (HER2).
In the 8MM, Italy had the highest diagnosed incidence of HER2+/HR+ breast cancer in 2020 (27.43 cases per 100,000 population), and urban China had the lowest diagnosed incidence in women in 2020 (10.10 cases per 100,000 population). The rate of increase was the highest in Spain, rising from 13.26 in 2010 to 18.23 in 2020. On the other hand, Germany had a decrease in the incidence rate from 2010-2020.
The major drivers of growth in the forecast period in the 8MM are:
- Approval and launch of premium-priced therapeutics in the 8MM during the forecast period: two small molecule inhibitors (Ibrance and Piqray), two antibody-drug conjugates (trastuzumab duocarmazine and disitamab vedotin), and a checkpoint inhibitor (Tecentriq)Label expansion of established drugs like Enhertu and Tukysa into earlier, more lucrative lines of therapy
- Label expansions of established drugs like Enhertu and Tukysa into earlier, more lucrative lines of therapy
- Reformulation of established blockbusters like Perjeta and Herceptin into a branded subcutaneous, fixed-dose form which will reduce the impact of biosimilar erosion
- Increased disease incidence across the 8MM
The major barriers to growth in the forecast period in the 8MM are:
- Patent expiries of the leading brands across the 8MM, in particular Perjeta, Herceptin, and Kadcyla, which constituted the majority of sales in 2020
- Increased cost-consciousness limiting the uptake of branded therapies and novel agents in Europe and Asia
- Very efficacious and tolerable therapies in the treatment paradigm, which means the indication is a highly competitive space to enter
What are the key regions and countries in 8MM HER-2 + breast cancer market?
In 2020, the US led the sales of HER2+ breast cancer therapies followed by, Germany, China, and Japan.
The US, 5EU, and Japan’s relative global market shares are expected to remain constant over the forecast period while China’s global market share is expected to increase.
The US market is the largest of the 8MM and accounted for an estimated more than 50% of sales in 2020. This is due to the large patient population and comparatively higher prices in the country. Sales in the HER2+ market are dominated by HER2-directed monoclonal antibodies (Herceptin and Perjeta) and an antibody-drug conjugate (Kadcyla), due to extensive use in the adjuvant and metastatic settings.
The HER2+ breast cancer market in the 5EU is forecast to grow at a CAGR of 0.2% during the forecast period and will experience the weakest growth out of the 8MM. Due to earlier the patent expiry of Herceptin in Europe (2017) than in the US and subsequent higher biosimilar erosion, Perjeta and Kadcyla are market leaders across the 5EU markets, although this may differ depending on the individual region.
The Urban China market is expected to increase significantly in size by 2030. GlobalData anticipates China to become the fastest-growing market among the 8MM, with a CAGR of more than 5% during the forecast period. Distinct drivers of growth in the Chinese market include a significant increase in the diagnosed incident population over the forecast period and the development of domestically developed drugs in China.
Market report scope
|Market size (Year – 2020)||$10.4 billion|
|Growth rate||CAGR >1% from 2021 to 2030|
|Base year for estimation||2020|
|Key players||Genentech/Roche, AstraZeneca, Daiichi Sankyo, Pfizer (Ibrance), Novartis (Piqray), Byondis (trastuzumab duocarmazine), and Remegen (disitamab vedotin)|
|Countries Covered||US, France, Germany, Italy, Spain, UK, China and Japan.|
This report covers opportunities for various marketed agents and pipeline agents in development across the 8MM, clinical and commercial assessments for agents in late-stage clinical development, R&D strategies, and innovative approaches in development for HER2+ breast cancer. This edition provides an update to the previous sales forecast for marketed and pipeline agents and highlights expected market dynamics by country and class of therapy across the forecast period, 2020-2030.
- Overview of HER2+ breast cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline HER2+ market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HER2+ therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
- Analysis of the current and future market competition in the global HER2+ market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global HER2+ therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2+ market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track drug sales in the global HER2+ therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Puma Biotechnology Novartis
Jiangsu HengRui Medicine
Table of Contents
Table of Contents
| About GlobalData
1 HER2+ Breast Cancer: Executive Summary
1.1 The HER2+ Breast Cancer Market Will Expand to
12.1B in 2030
1.2 Roche/Genentech to Maintain its Leading Position Despite Competition from Biosimilars and Enhertu
1.3 Treatment of Brain Metastases, Intratumor Heterogeneity, and Improving Patient Outcomes Remain the Unmet Needs
1.4 Novel Antibody-Drug Conjugates and Established Breast Cancer Drugs Populate the Late-Stage Pipeline
1.5 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for All Invasive and HER2-Positive Breast Cancer (2020-2030)
4.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer
4.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer
4.5.3 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer
4.5.4 Diagnosed Incident Cases of HER2+/HR- Breast Cancer
4.5.5 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stages
4.5.6 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stages
4.5.7 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status
4.5.8 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status
4.5.9 Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression
4.5.10 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression
4.5.11 Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression
4.5.12 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis
4.5.13 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis
4.5.14 Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression
4.5.15 Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
5.2.2 Neoadjuvant/Adjuvant Treatment Paradigm
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
7.2 Improving Curative Options and Patient Outcomes
7.3 Treatment of Patients with Brain Metastases
7.4 Stratifying Patients According to Molecular Profiles and Reducing Toxicities of Existing Regimens
7.5 Treating Intratumor Heterogeneity
8 R&D Strategies
8.1.2 Development of Subcutaneous and Fixed Dose Formulations of Blockbusters
8.1.3 Label Expansions into Earlier Lines of Therapy
8.1.4 Novel Therapeutic Approaches to Treating HER2+ Breast Cancer
8.2 Clinical Trials Design
8.2.1 Preferred Primary Outcomes Measures Dependent on Line of Therapy
8.2.2 Increased Utility of Quality of Life and Patient Reported Outcome Measures
8.2.3 Assessment of Novel Biomarkers to Predict Response
9 Pipeline Assessment
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.2 Competitive Assessment
11 Current and Future Players
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.2 Drivers and Barriers – Global Issues
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5.2 Key Events
12.5.3 Drivers and Barriers
13.3.1 Forecasting Methodology
13.4 Primary Research – KOLs Interviewed for This Report
13.5 Primary Research – Prescriber Survey
13.6 About the Authors
13.6.2 Therapy Area Director
13.6.4 Managing Epidemiologist
13.6.5 Global Director of Therapy Analysis and Epidemiology
13.6.6 Global Head and EVP of Healthcare Operations and Strategy
| Contact Us
Frequently asked questions
What is the market value for the HER2+ breast cancer market in 2020?
The total market size of the HER2+ breast cancer market was valued at $10.4 billion in 2020.
What is the growth rate of the HER2+ breast cancer market?
The HER2+ breast cancer market is projected to grow at a CAGR of more than 1% during the period 2021-2030.
Who are the key market players in the HER2+ breast cancer market?
Genentech/Roche, AstraZeneca, Daiichi Sankyo, Pfizer (Ibrance), Novartis (Piqray), Byondis (trastuzumab duocarmazine), and Remegen (disitamab vedotin) are the key players in HER2+ breast cancer market.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.